- Home
- SUPN vs RQI Comparison
SUPN vs RQI Comparison
Compare SUPN & RQI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- RQI
- Stock Information
- Founded
- SUPN 2005
- RQI 2002
- Country
- SUPN United States
- RQI United States
- Employees
- SUPN N/A
- RQI N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- RQI Trusts Except Educational Religious and Charitable
- Sector
- SUPN Health Care
- RQI Finance
- Exchange
- SUPN Nasdaq
- RQI Nasdaq
- Market Cap
- SUPN 2.1B
- RQI 1.7B
- IPO Year
- SUPN 2012
- RQI N/A
- Fundamental
- Price
- SUPN $33.05
- RQI $12.93
- Analyst Decision
- SUPN Hold
- RQI
- Analyst Count
- SUPN 2
- RQI 0
- Target Price
- SUPN $36.00
- RQI N/A
- AVG Volume (30 Days)
- SUPN 464.2K
- RQI 432.6K
- Earning Date
- SUPN 02-25-2025
- RQI 01-01-0001
- Dividend Yield
- SUPN N/A
- RQI 8.20%
- EPS Growth
- SUPN 130.79
- RQI N/A
- EPS
- SUPN 1.07
- RQI N/A
- Revenue
- SUPN $651,972,000.00
- RQI N/A
- Revenue This Year
- SUPN $7.94
- RQI N/A
- Revenue Next Year
- SUPN N/A
- RQI N/A
- P/E Ratio
- SUPN $31.70
- RQI N/A
- Revenue Growth
- SUPN 6.79
- RQI N/A
- 52 Week Low
- SUPN $25.53
- RQI $9.17
- 52 Week High
- SUPN $40.28
- RQI $12.64
- Technical
- Relative Strength Index (RSI)
- SUPN 32.98
- RQI 55.60
- Support Level
- SUPN $32.53
- RQI $12.78
- Resistance Level
- SUPN $39.99
- RQI $13.05
- Average True Range (ATR)
- SUPN 1.31
- RQI 0.17
- MACD
- SUPN -0.69
- RQI 0.00
- Stochastic Oscillator
- SUPN 6.71
- RQI 76.92
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the Fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.